The Milan Cell and Gene Center of Excellence at AGC Biologics will produce LVV material for Treg cell therapy candidates.

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by ...

Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs ...

AGC Biologics has partnered with Quell Therapeutics to support the development of multiple Treg cell therapy drug candidates.

Creative Biolabs upgrades its therapeutic antibody and protein development platform, with enhanced capabilities in endotoxin ...

ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in 2H 2026 that will provide ...

ADMA Biologics has surged 1,314% since 2021 with soaring revenue, ASCENIV demand, and strong financials. Learn why ADMA stock ...

Makers of organoids and cell models cheered the decision and said it will bolster the development of precision medicines, ...

On April 10, 2025, the US Food and Drug Administration (FDA) announced its intent to phase out the use of animal testing in the development of ...

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal ...

Operator: Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2025 Conference Call. I am George, the Chorus ...

The transition from preclinical development to clinical trials is a critical, with approximately 89% of drugs failing. Nearly half of these failures stem from unexpected and unmanageable human ...